Thatcher, Nick
The Christie Hospital · The Christie NHS Foundation Trust
5 papers on CoChat
Most cited papers
- Verified
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 2,079
- Verified
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 703
- Verified
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., et al. (2015) · Drugs
Lung Cancer Treatments and MutationsChemotherapy-related skin toxicity
Cited by 152
- Verified
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Szczesna, A., et al. (2015) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 133
- Verified
1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
Paz-Ares, L., Socinski, M. A., Shahidi, J., Hozak, R. R., Soldatenkova, V., Thatcher, N., & Hirsch, F. (2016) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 4
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free